Yuhan Corporation

KOSE:A000100 Stock Report

Market Cap: ₩9.0t

Yuhan Valuation

Is A000100 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A000100 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A000100 (₩119700) is trading above our estimate of fair value (₩107621.71)

Significantly Below Fair Value: A000100 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A000100?

Key metric: As A000100 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A000100. This is calculated by dividing A000100's market cap by their current earnings.
What is A000100's PE Ratio?
PE Ratio60.7x
Earnings₩147.85b
Market Cap₩8.97t

Price to Earnings Ratio vs Peers

How does A000100's PE Ratio compare to its peers?

The above table shows the PE ratio for A000100 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.5x
A128940 Hanmi Pharm
19.6x7.4%₩3.6t
A069620 Daewoong Pharmaceutical
16.1x17.2%₩1.5t
A237690 ST PharmLtd
80.7x40.1%₩1.8t
A185750 Chong Kun Dang Pharmaceutical
5.8x-21.8%₩1.2t
A000100 Yuhan
60.7x21.3%₩9.0t

Price-To-Earnings vs Peers: A000100 is expensive based on its Price-To-Earnings Ratio (60.7x) compared to the peer average (30.5x).

Price to Earnings Ratio vs Industry

How does A000100's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A007370 Jin Yang Pharmaceutical
2.4xn/aUS$48.50m
No more companies available in this PE range
A000100 60.7xIndustry Avg. 14.6xNo. of Companies8PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A000100 is expensive based on its Price-To-Earnings Ratio (60.7x) compared to the KR Pharmaceuticals industry average (14.6x).

Price to Earnings Ratio vs Fair Ratio

What is A000100's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A000100 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio60.7x
Fair PE Ratio27.6x

Price-To-Earnings vs Fair Ratio: A000100 is expensive based on its Price-To-Earnings Ratio (60.7x) compared to the estimated Fair Price-To-Earnings Ratio (27.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A000100 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩119,700.00
₩125,937.50
+5.2%
28.5%₩220,000.00₩75,000.00n/a16
Nov ’25₩134,800.00
₩122,200.00
-9.3%
30.9%₩220,000.00₩75,000.00n/a15
Oct ’25₩142,600.00
₩111,533.33
-21.8%
30.8%₩220,000.00₩67,000.00n/a15
Sep ’25₩141,000.00
₩100,470.59
-28.7%
16.3%₩134,000.00₩67,000.00n/a17
Aug ’25₩92,000.00
₩98,210.53
+6.8%
16.3%₩134,000.00₩67,000.00n/a19
Jul ’25₩83,800.00
₩89,751.88
+7.1%
15.7%₩125,000.00₩65,000.00n/a19
Jun ’25₩68,800.00
₩87,626.19
+27.4%
15.1%₩125,000.00₩65,000.00n/a20
May ’25₩72,400.00
₩86,202.49
+19.1%
15.7%₩125,000.00₩65,000.00n/a20
Apr ’25₩79,200.00
₩83,362.02
+5.3%
11.9%₩110,000.00₩65,000.00n/a20
Mar ’25₩67,400.00
₩82,612.02
+22.6%
12.4%₩110,000.00₩65,000.00n/a20
Feb ’25₩59,100.00
₩83,864.78
+41.9%
20.2%₩142,857.14₩66,666.67n/a19
Jan ’25₩68,800.00
₩82,389.31
+19.8%
21.3%₩142,857.14₩62,585.04n/a19
Dec ’24₩58,571.43
₩82,606.52
+41.0%
21.7%₩142,857.14₩56,190.48n/a19
Nov ’24₩55,047.62
₩82,328.04
+49.6%
22.4%₩142,857.14₩56,190.48₩134,800.0018
Oct ’24₩72,190.48
₩82,857.14
+14.8%
15.8%₩119,047.62₩56,190.48₩142,600.0018
Sep ’24₩67,142.86
₩78,897.24
+17.5%
13.3%₩95,238.10₩56,190.48₩141,000.0019
Aug ’24₩71,333.33
₩76,402.12
+7.1%
13.7%₩95,238.10₩56,190.48₩92,000.0018
Jul ’24₩57,523.81
₩69,841.27
+21.4%
10.6%₩85,714.29₩56,190.48₩83,800.0018
Jun ’24₩58,285.71
₩69,070.29
+18.5%
10.4%₩77,097.51₩51,428.57₩68,800.0019
May ’24₩54,857.14
₩68,485.26
+24.8%
10.5%₩77,097.51₩51,428.57₩72,400.0020
Apr ’24₩48,190.48
₩65,974.46
+36.9%
13.5%₩77,097.51₩39,047.62₩79,200.0019
Mar ’24₩50,190.48
₩66,839.43
+33.2%
13.3%₩78,004.54₩39,047.62₩67,400.0021
Feb ’24₩50,761.90
₩67,653.06
+33.3%
11.5%₩78,004.54₩41,723.36₩59,100.0020
Jan ’24₩54,476.19
₩67,019.42
+23.0%
11.9%₩78,004.54₩41,723.36₩68,800.0021
Dec ’23₩53,061.22
₩67,141.78
+26.5%
11.5%₩78,004.54₩41,723.36₩58,571.4321
Nov ’23₩54,784.58
₩67,764.17
+23.7%
11.5%₩78,004.54₩41,723.36₩55,047.6220

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Hugel

₩2.9t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,500.00

7D

-4.4%

1Y

79.2%

Medy-Tox

₩830.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩123,300.00

7D

-10.8%

1Y

-41.6%

J2KBIO

₩54.2b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,490.00

7D

-13.3%

1Y

n/a